From venetoclax/HMA combination studies to resistance profiling and biomarker-stratified response analysis, xCellSense® measures ex vivo drug response directly in primary AML cells to support candidate, combination, and translational development decisions.
Request Scientific Consultation
AML is molecularly heterogeneous and increasingly treated with combination regimens. Venetoclax/HMA backbones, emerging triplets, and resistance after venetoclax exposure create a need for functional data that complement genomic profiling.
1
Combination design
Test your asset alone and in combination with venetoclax, HMAs, or other standard-of-care agents—with quantitative dose-response, synergy analysis, and ranked combination performance.
2
Resistance profiling
Benchmark ex vivo activity across treatment-naïve and previously treated AML samples, including patients previously exposed to venetoclax or other standard-of-care regimens, subject to availability at study scoping.
3
Modality-specific readouts
Assess target expression and mechanism-specific pharmacodynamic readouts — receptor occupancy and target-protein degradation — for ADC, bispecific, and targeted-degrader programs, where supported by qualified reagents.
4
Biomarker correlation
Correlate ex vivo drug response with molecular features from the same specimen—including AML alterations such as FLT3, NPM1, IDH1/2, and TP53—to identify response-associated candidate biomarkers and generate biomarker-stratification hypotheses.
Generate functional evidence to prioritize combinations, characterize response in treatment-exposed AML, and refine response-associated biomarker hypotheses — before committing to early clinical development.
Key Deliverables
.svg)
A scientist — not a sales desk — will scope a tailored AML study and return a design and timeline.
